No Data
No Data
Full text of Jianmin Pharmaceutical Group's 2024 interim report.
Summary of Jianmin Pharmaceutical Group's H1 2024 report.
Jianmin Pharmaceutical Group (600976.SH): net income of 0.239 billion yuan in the first half of the year, a year-on-year decrease of 5.16%.
Jianmin Pharmaceutical Group (600976.SH) released its semi-annual report on August 15th, revealing a 7.02% YoY decrease in revenue of 2.01 billion yuan and a 5.16% YoY decrease in net income attributable to shareholders of listed companies, which was 0.239 billion yuan in the first half of 2024. The company adheres to the concept of innovation leading enterprise development and continues to increase research and development investment. By means of independent research and development, technology introduction and other methods, the project establishment and R&D process of innovative drugs, including Niuhuang children's fever relieving patch, Zhishi Tongbian granules and Tongjiang granules, progressed smoothly, and new projects were initiated in the field of traditional Chinese medicine.
Jianmin Pharmaceutical Group (600976.SH) currently has 25 new drug projects under development, including several innovative traditional Chinese medicine products such as Niuhuang pediatric fever-reducing patches, Tongjiang granules, and Zhishi Tongbian gr
Jianmin Pharmaceutical Group (600976.SH) stated during a specific research interview that the company has a rich product line of prescription drugs. Among the single products that sold more than one billion yuan in 2023 are Jianpi Shengxue Tablets, Xiaojin Capsules, Children's Baotai Health Granules, and Estradiol Gel. In recent years, there are also newly launched innovative drugs in the field of traditional Chinese medicine, including Baidu Shengji Powder, Class 1 innovative drug Qirui Stomach Relax Capsules and Children's Purple Pearl Lung Syrup. All the above products have significant clinical efficacy and great product strength. At the same time, the company continues to increase research and development investment, accelerating the investigation and research on innovative drugs of traditional Chinese medicine, common diseases in children, and common diseases with high incidence rate. In the first half of this year, the company is still in the research stage.
Jianmin Pharmaceutical Group (600976.SH): There is not much price difference for the company's products sold between various provinces and cities in China, and the price control of "four same pharmaceuticals" has not had a negative impact on the company's
Jianmin Pharmaceutical Group (600976.SH) stated during a specific object investigation that, according to the notice on promoting fair, honest, transparent, and balanced inter-provincial pricing of pharmaceuticals with the same generic name, brand name, dosage form and specification released by the National Healthcare Security Administration Office on January 5, 2024, the four same drugs refer to pharmaceuticals with the same generic name, brand name, dosage form, and specification. The objective of this governance is to basically eliminate unfair and discriminatory high prices between provinces by the end of March 2024. There is not much difference in the prices of the company's products sold in various provinces and cities across the country, and the price governance of the four same drugs has not affected the sales of the company's products.
Jianmin Pharmaceutical Group (600976.SH): Two products have obtained pharmaceutical registration certificates.
On July 5, Gelonhui reported that Jianmin Pharmaceutical Group (600976.SH) recently received the Drug Registration Certificates for Pregabalin Oral Solution and Diquafosol Sodium Eye Drops issued and approved by the National Medical Products Administration. Pregabalin oral solution is indicated for the treatment of post-herpetic neuralgia and fibromyalgia. Pregabalin is a structural derivative of the inhibitory neurotransmitter γ-aminobutyric acid (GABA) and has high affinity for the α2-δ site (an auxiliary subunit of voltage-gated calcium channels) in central nervous system tissues. It is mainly used to treat post-herpetic neuralgia and fibromyalgia. Diquafosol sodium
No Data